MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
A one-shot gene-editing cholesterol therapy could soon be a reality
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
Clears major obesity endpoints at 80 weeks
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Transition to a fermentation-based globally integrated CDMO platform
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
